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Di(2-ethylhexyl) phthalate (DEHP) is a persistent organic pollutant that is added to increase 
the flexibility of soft plastics, such as polyvinyl chloride (PVC). Since DEHP is not bound to 
the polymer, it leaches into the environment, leading to human exposure. When DEHP is 
metabolized by the body, it is cleaved into mono-(2-ethylhexyl) phthalate (MEHP). MEHP is 
then oxidized to produce the secondary-oxidized metabolites mono-(2-ethyl-5-
carboxypentyl)phthalate (5cx-MEPP), mono-(2-ethyl-5-oxohexyl)phthalate (5oxo-MEHP), 
and mono-[2-(carboxymethyl)hexyl]phthalate (2cx-MMHP). DEHP and its metabolites 
interact with peroxisome proliferator-activated receptors (PPARs), which can alter lipid 
metabolism. To synthesize 5cx-MEHP, an enolate alkylation was performed with ethyl 
butyrate to form ethyl 2-ethyl-6-heptenoate. A reduction with LiAlH4 was performed to 
produce 2-ethyl-6-hepten-1-ol. The alcohol was esterified with phthalic anhydride and 
subsequently oxidized to produce 5cx-MEHP. This procedure was then repeated to 
synthesize 2cx-MMHP and 5oxo-MEPP, replacing the enolate alkylation with a malonic 
ester alkylation and modifying the final oxidation. Binding of the metabolites of DEHP to 
PPARγ can be assessed using a thermal shift assay. A protocol for the thermal shift assay 
was developed using the binding of PPARγ and rosiglitazone, a known PPARγ ligand. 
Information gained surrounding the binding of DEHP and its metabolites to PPARγ may 
explain the endocrine disrupting effects seen from exposure to phthalate plasticizers by 
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Di(2-ethylhexyl) phthalate and its metabolism 
 
Di(2-ethylhexyl) phthalate (DEHP) (1), is a persistent organic pollutant found 
ubiquitously in the environment. DEHP (1) is used as a plasticizer in polyvinyl chloride 
(PVC) plastics.1,2 A plasticizer is a substance that is used to increase the flexibility of plastics 
by acting as a molecular lubricant that fits between polymer chains.3 PVC plastics are 
frequently found in medical devices and other commercial products. Persistent organic 
pollutants refer to organic compounds incapable of readily breaking down in the 
environment. Since DEHP (1) is not chemically bound to the PVC polymer, it can leach into 
the environment, leading to human exposure via inhalation, ingestion, and absorption through 
the skin and mucous membranes.2,4 Toxicological effects of DEHP (1) have been linked to 
developmental toxicity in animals, hepatocarcinogenesis in rodents, and embryotoxicity in 
rats and mice, as well as autism spectrum disorders and obesity in humans.5,6,7,8 
When DEHP (1) is metabolized by the body, it is cleaved into mono-(2-ethylhexyl) 
phthalate (MEHP) (2) and 2-ethylhexanol (3).2 This process is catalyzed by esterases and 
lipases in the pancreas.9,10  MEHP is then oxidized by several cytochrome P450 (CYP) 
isoforms, including CYP2C9 and CYP2C19, which are fatty acid omega hydroxylases that 
act to oxidize organic molecules in the first phase of drug metabolism.9 This first phase is 
important for converting the organic molecules to more polar, water-soluble metabolites that 
can be excreted in the urine.11 The resulting metabolites are further oxidized by alcohol 
dehydrogenase (ADH) or aldehyde dehydrogenase (ALDH) to produce the secondary-
oxidized metabolites mono-(2-ethyl-5-oxohexyl) phthalate (5oxo-MEHP) (7), mono-(2-
8 
 
ethyl-5-carboxypentyl) phthalate (5cx-MEPP) (8), and mono-[2-(carboxymethyl) hexyl] 








The oxidative metabolites of DEHP (1) have been studied as biomarkers of DEHP (1) 
exposure.4,12 It was discovered previously that concentrations of the secondary-oxidized 
metabolites in human urine is higher than DEHP (1) or MEHP (2) alone.4,12,13 Additionally, it 
has been posited that the metabolites themselves may be the cause of the toxic effects of 
9 
 
DEHP (1).14 However, these previous studies neglect to identify which of the metabolites 
may have the greatest effect on toxicity. 
 
Phthalate toxicity 
DEHP (1) falls under the broader class of chemicals known as phthalates, or phthalate 
esters, which are esters of phthalic anhydride as seen in Figure 1. 
 
 
Figure 1. A generic phthalate ester, where R is a branched or linear alkyl chain. The two R 
groups need not be the same. 
 
 
Phthalates are known endocrine-disrupting chemicals (EDCs), which are chemicals that alter 
the function and regulation of the endocrine system.4,15 EDCs typically function through 
interaction with nuclear receptors which leads to altered gene expression.15 Peroxisome 
proliferator-activated receptors (PPARs) are a type of nuclear receptors with which DEHP 
(1) is known to interact.16  
 
Peroxisome Proliferator-Activated Receptors (PPARs) 
Peroxisome proliferator-activated receptors (PPARs) are a family of proteins that are 
lipid-activated nuclear receptors. Nuclear receptors are a superfamily of transcription factors 
10 
 
that regulate homeostasis and development.16 PPARs are divided into three subtypes, 
PPARα, PPARβ/δ, and PPARγ.17 Each receptor is involved lipid metabolism; therefore 
disruption of PPAR action can cause an alteration in the regulation of energy maintenance 
and homeostasis within the body.5,6,8 PPARα is expressed primarily in the liver, and regulates 
fatty acid oxidation.17 PPARβ/δ is expressed ubiquitously in the body, and its primary 
functions are fatty acid metabolism and the suppression of inflammation caused by 
macrophages.17 PPARγ, which was the receptor of focus in this research, is expressed 
primarily in adipose tissue and regulates adipocyte differentiation and energy storage.17 The 
structure of PPARγ is shown in Figure 2A.  
A.  
B.  
Figure 2. A. Cartoon X-ray diffraction structure of PPARγ ligand binding domain bound to 




PPARγ is the target of a drug known as rosiglitazone, shown in Figure 2B, which is used to 
treat diabetes type II and insulin resistance. Rosiglitazone binds to the ligand binding domain 
of PPARγ and initiates the PPARγ transcriptional cascade, making it a PPARγ agonist.6 It is 
known that MEHP (2) binds to PPARγ in a similar manner, acting as a less potent agonist.6, 19 
The predicted binding pocket interactions of PPARγ with MEHP (2) is shown in Figure 3 
compared to the binding of rosiglitazone.19  
 
 
Figure 3. Binding of rosiglitazone to the LBD of PPARγ compared to the predicted binding 
pocket interactions of MEHP.19  
 
 
It can be predicted that the secondary-oxidized metabolites of DEHP (1) would also bind to 
PPARγ with similar pathophysiological consequences. This study proposes to examine the 
binding of PPARγ to rosiglitazone and the secondary-oxidized metabolites of DEHP (1) 






Synthesis of the oxidative metabolites of DEHP 
The purpose of this research is to synthesize the secondary-oxidized metabolites of 
DEHP (1) and perform a thermal shift assay to assess metabolite binding with the PPARγ 
ligand binding domain (LBD). This research addresses the need to understand the 
metabolism of persistent organic pollutants and helps to explain the endocrine disrupting 
effects seen from exposure to phthalate plasticizers such as DEHP (1) by addressing the 
fundamental question of their cellular targets. Information gained from this research project 
surrounding the toxicity of DEHP (1) and its metabolites may be extended to other phthalates 
and aid in the understanding of the mechanism behind the toxicity of persistent organic 
















II. Results and Discussion 
Synthesis of the secondary oxidized metabolites 
 Initial attempts to synthesize metabolites 5oxo-MEHP (7), 5cx-MEPP (8), and 2cx-
MMHP (9) utilized the malonic ester alkylation. Synthesis of 2cx-MMHP (9) (Scheme 2) 
was initiated using the procedure outlined by Kelly McDaniel in her previous research on the 
synthesis of the oxidative metabolites of DEHP (1).  
 
 
Scheme 2. Synthesis of 2cx-MMHP (9) 
 
The first step is a malonic ester alkylation, which is shown in Figure 4. The synthesis 
followed a modified procedure in which diethyl allylmalonate (10) was alkylated with allyl 
bromide.20 The NaH first deprotonates the malonate and the malonate then performs an SN2 
reaction with the alkyl halide to form a new carbon-carbon bond. Since iodide is a better 
leaving group than bromide, NaI was added to the reaction to form allyl iodide in situ. It was 
believed this would promote the alkylation of diethyl allylmalonate (10). This reaction 
14 
 
allowed for the production of diethyl allylbutylmalonate (11), the presence of which was 
verified using 1H NMR (Figure 19).  
 
 
Figure 4. Malonic ester alkylation mechanism 
 
Following the malonic ester alkylation, two possible synthetic methods for the formation of 
the monoester 2-allyl-hexanoate (12) were proposed. First, a base hydrolysis of the malonic 
ester (11) using KOH in the presence of H2O and EtOH with a subsequent decarboxylation 
was attempted as used previously by Kelly McDaniel. However, several attempts were made 
using this reaction starting with diethyl allylbutylmalonate (11) with the determination that 
the hydrolysis was not entirely successful. The hydrolysis produced allylbutylmalonic acid, 
which was desired, and 2-(allylbutyl)malonic acid ethyl ester (Figure 5), which is only a 
partial hydrolysis, based on GC-MS of the product (Figure 6). Additionally, the heat involved 
in the hydrolysis also resulted in the partial decarboxylation of the two hydrolysis products. 




             A.   B.  
Figure 5. Allylbutylmalonic acid (a) and 2-(Allylbutyl)malonic acid ethyl ester (b) 
 
 
Figure 6. GC-MS of diethyl allylbutylmalonate hydrolysis reaction 
 
 
Scheme 3. Hydrolysis and decarboxylation of diethyl allylbutylmalonate (11) 
 
Based on the large mixture of products involved in this reaction, it was determined that the 
Krapcho decarboxylation would be a suitable replacement, given that it would eliminate the 
16 
 
need for a hydrolysis step. A modified version of the procedure described by Krapcho, et al. 
was used in which 3 equivalents of LiCl were added per mole of the alkylated diester (11) in 
a mixture of DMSO and H2O.21 The Krapcho decarboxylation, shown in Figure 7, was 
successful, as evidenced by the production of the monoester ethyl 2-allylhexanoate (12) 
based on the 1H NMR shown in Figure 20. However, the yield remained low. This issue 
could be alleviated in the future with the use of a methyl ester rather than ethyl ester as the 
reaction takes place as an SN2 reaction in which the chloride ion acts as a nucleophile and 
attacks the electrophilic carbon in the ester resulting in an electron rearrangement that causes 
the loss of one of the carboxyl groups in the malonate. The steric hindrance of the methyl 
ester is lower than that of the ethyl ester which would increase the likelihood of the 
occurrence of an SN2 reaction. 
 
 
Figure 7. Krapcho decarboxylation of malonic esters 
 
Following the Krapcho decarboxylation, a LiAlH4 reduction was used to form 2-allyl-1-





Figure 8. LiAlH4 reduction of ethyl 2-allylhexanoate (12) 
 
A subsequent esterification of the resulting alcohol from the LiAlH4 reduction was performed 
using phthalic anhydride in pyridine. Then, a ruthenium catalyzed oxidation of the allyl 
double bond was performed to form 2cx-MMHP (9) (Scheme 4).  
 
 
Scheme 4. Esterification and oxidation of 2-allyl-1-hexanol (13) 
18 
 
As shown in Scheme 5, the synthesis of 5oxo-MEHP (7) followed a similar pattern, 
with the substitution of the starting material with diethyl ethylmalonate (15) and the 





Scheme 5. Synthesis of 5oxo-MEHP (7) 
 
The Wacker oxidation is shown in Scheme 6. This reaction oxidized the double bond in 





Scheme 6. Esterification and oxidation of 2-ethyl-5-hexenol (18) 
 
The presence of 2cx-MMHP (9) and 5oxo-MEHP (7) were verified with 1H NMR 
(Figures 23 and 28). The structures of 2cx-MMHP (9) and 5oxo-MEHP (7) with their 
respective 1H NMR peaks labeled are shown in Figures 9 and 10.  
 
 
Figure 9. 2cx-MMHP (9) with labeled 1H NMR peaks 
 




The 1H NMR of 2cx-MMHP (9) shows some contamination with n-hexanes based on the 
triplet peak at 0.89 ppm. The carboxylic acid peak, which contains both carboxylic acids in 
the structure, is far lower than a typical carboxylic acid peak at 8.38 ppm. The increased 
shielding of the hydrogen atoms on the carboxylic acids that caused a lower shift than the 
expected peak is potentially caused by an intramolecular interaction that must be studied 
further. The 1H NMR of 5oxo-MEHP (7) was significantly contaminated with 
dimethylformamide (DMF), which was the solvent used in the Wacker oxidation of mono(2-
ethyl-5-hexenyl)phthalate. The peaks of DMF are present at 8.01 ppm, 2.99 ppm, and 2.88 
ppm, each of which also corresponds to the chemical shifts of protons on 5oxo-MEHP (7), 
specifically the carboxylic acid on the aromatic ring, the protons of the terminal alkane, and 
those of a methylene group internal to the structure.22 The lower chemical shift caused by the 
increased shielding of the carboxylic acid protons that resulted in a peak at 8 ppm instead of 
the expected chemical shift of 10-12 ppm also occurred in 5oxo-MEHP (7). Once again, this 
may be due to an intramolecular interaction that results in the shielding of the carboxylic acid 
proton. Additionally, there appears to be residual diethyl ether based on the peaks at 3.48 
ppm and 1.21 ppm.22 The peaks near 1.21 ppm correspond to the ethyl group on 5oxo-MEHP 
as well.  
A synthesis similar to that used in the formation of 2cx-MMHP (9) and 5oxo-MEHP 
(7) was initiated to form 5cx-MEPP (8). Scheme 7 details the approach used in the previous 
synthesis attempts of 5cx-MEPP (8) that follows the model of 2cx-MMHP (9) and 5oxo-
MEHP (8) in which a malonic acid alkylation (20) is followed by the Krapcho 
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decarboxylation (21a) before performing a LiAlH4 reduction (22) followed by esterification 
(23) and oxidation (8).23  
 
 
Scheme 7. Proposed synthesis of 5cx-MMHP (8) 
 
Most similar to 5oxo-MEHP (7), diethyl ethylmalonate (15) was used as the starting material, 
with 5-iodo-1-pentene (24) as the alkyl halide, which was synthesized as shown in Scheme 8.  
 
 
Scheme 8. Synthesis of 5-iodo-1-pentene (24) 
 
The malonic acid alkylation occurred without complication; however, the Krapcho 
decarboxylation suffered significant difficulties. The reaction time, already long in the 
formation of monoesters (12) and (17), was increased in an effort to increase the yield of the 










Figure 11. GC-MS of Krapcho decarboxylation reaction progress. A. GC of the Krapcho 
decarboxylation after 8 hours. B. GC of the Krapcho decarboxylation after 24 hours. C. MS 
of selected peaks from the GC shown in 11B.  
 
The expected monoester ethyl 2-ethyl-6-heptenoate (21a) failed to form in any significant 
quantity. As can be seen in Figure 11A, after 8 hours at 180 ℃, only a small amount of 
product had formed, while a large amount of starting material remained. Figure 11B shows 
the reaction after 24 hours on heat and shows that several other products were present in the 
24 
 
mixture of product and starting material. This was unanticipated, as the sole difference 
between the alkylation products (16) and (20) was the alkyl chain of the alkyl halide. The 
five-carbon chain that originated in 5-iodo-1-pentene (24) appeared to either cause a 
significant disruption to the mechanism of the Krapcho decarboxylation or to cause the rapid 
decomposition of the product. One of the decomposition peaks was identified as a potential 
cyclization reaction referred to as the Conia-Ene reaction shown in Figure 12. A four-carbon 
chain would form too unstable a ring, which is why that would be unlikely to occur in the 
formation of 2-ethyl-5-hexenoate (17). The five-carbon chain in ethyl 2-ethyl-6-heptenoate 
(21a) would, on the other hand, potentially form a ring structure from the pentene chain in 
the presence of heat.24  
 
 
Figure 12. Conia-Ene reaction of ethyl 2-ethyl-6-heptenoate (21a) 
 
Although the MS of the second peak present in the GC does not appear to contain the 
expected mass peak of the Conia-Ene reaction product at 184 m/z as shown in Figure 11C, 
the fragments shown may correspond with the Conia-Ene five carbon ring. The peak at 182 
m/z would be the M – H2 peak, and the peak at 153 m/z would be the fragmentation of the 
ethyl group on the ester. The lack of a corresponding M peak is does not necessarily rule out 
the Conia-Ene reaction, but it does indicate that further study may be needed to understand 
the intramolecular rearrangement that resulted in the loss of H2. Additionally, a peak that was 
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characteristic in all other derivatives of the Krapcho reaction with diethyl (3-
pentenyl)ethylmalonate (20) was at 116 m/z, which is the McLafferty rearrangement that 
results in the loss of the pentenyl group as shown in Figure 13. 
 
 
Figure 13. McLafferty rearrangement of diethyl 2-ethyl-6-heptenoate (21a) 
 
This peak was not present in this fraction of the GC-MS, which indicates that the pentenyl 
group was not present for the McLafferty rearrangement to occur. The failure of the Krapcho 
decarboxylation as a result of the decomposition of the product of the decarboxylation before 
a sufficient amount could be recovered, lead to the decision to pursue a new synthesis 
pathway that would allow the direct formation of the desired monoester ethyl 2-ethyl-6-
heptenoate (21a).  
An alternative approach for the synthesis of 5cx-MEPP (8) was proposed as shown in 
Scheme 9. In this procedure, the monoester starting material is first deprotonated by sodium 
bis(trimethylsilyl)amide (NaHMDS) to form an enolate which can then be attacked by an 






Scheme 9. Alternative synthesis of 5cx-MEPP (8) 
 
The rest of the synthesis is identical to that shown in Scheme 2, where the ester (21b) is 
reduced by LiAlH4 to form 2-ethyl-6-heptenol (22). The alcohol is then esterified in reaction 
with phthalic anhydride, with pyridine acting as a base. Oxidation of mono(2-ethylheptenyl) 
phthalate (23) with ruthenium trichloride and sodium periodate results in the cleavage of the 
terminal alkene to a carboxylic acid, forming 5cx-MEPP (8). 
This enolate alkylation allows for the direct synthesis of ethyl 2-ethyl-6-heptenoate 
(21b) from ethyl butyrate (25) and 5-iodo-1-pentene (24) in the presence of NaHMDS in 
THF at -78℃. A modified literature procedure in which 1.2 equivalents of NaHMDS were 
used was followed as shown in Scheme 10.25 
 
 




After the enolate alkylation of ethyl butyrate (25), the rest of the synthesis was identical to 
that shown for 2cx-MMHP (9) and 5oxo-MEHP (7) where the monoester (21b) was reduced 
by LiAlH4 producing 2-ethyl-6-heptenol (22). The alcohol was esterified with phthalic 
anhydride to produce mono(2-ethyl-6-heptenyl) phthalate (23) and subsequently oxidized 
using a ruthenium-catalyzed reaction to produce 5cx-MEPP (8) as shown in Scheme 15.  
 
 
Scheme 11. LiAlH4 reduction, esterification with phthalic anhydride, and oxidation of  
ethyl 2-ethyl-6-heptenoate (21b) 
 
The presence of 5cx-MEPP (8) was verified with 1H NMR shown in Figure 32. The structure 






Figure 14. 5cx-MEPP (8) with labeled 1H NMR peaks 
 
The carboxylic acid peaks of 5cx-MEPP (8), similar to the other two secondary oxidized 
metabolites, are shielded and appear at a lower shift of 8.5 ppm. The peak is broad, and 
therefore was not integrated as the integral would not be accurate. The reason behind the 
shielding of the carboxylic acid peaks for all three secondary oxidized metabolites must be 
investigated further. The sample was also contaminated with dichloromethane (DCM), with a 
singlet peak at 5.24 ppm, methanol, with a peak at 3.49 ppm, and acetic acid, with a peak at 
2.05 ppm.22 These solvents were used to purify the sample but were difficult to remove 
following purification. Additionally, there appeared to be some n-hexanes that remained in 
the sample based on the triplet peak at 0.86 ppm and the multiplet at 1.38 ppm.22 
 
Thermal shift assay 
The binding of the metabolites of DEHP to PPARγ can be studied through the use of 
a thermal shift assay (TSA).26 A common TSA protocol and results are shown in Figure 15. 
Proteins, such as PPARs, have a characteristic melting point (TM) at which the temperature is 
high enough to result in denaturation of 50% of the protein and the loss of protein tertiary 
structure.26 When a ligand binds to a protein, the melting point of the protein may change. 
The melting point will typically increase, given that proteins are generally stabilized by 
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ligand binding, and the change is directly proportional to the ligand-binding affinity.26,27,28 
TSAs rely on fluorescence; changes in fluorescence are measured as the temperature is 





Figure 15. A. The effect of temperature on the denaturation of a ligand-bound protein and the 
fluorescence of SYPRO Orange dye. B. Sample melt curve plot of fluorescence versus 
temperature. The curve ends at the TM.31 
 
Protein tertiary structure formation relies on hydrophobic collapse, which refers to the 
tendency of the hydrophobic regions of the protein to fold together to the interior of the 
protein and is a result of the interactions between the hydrophobic amino acids of the protein. 
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This causes the internal regions of the protein to be primarily hydrophobic. As the protein is 
denatured, the hydrophobic interior is exposed, allowing the binding of the fluorescent dye to 
this hydrophobic core as shown in image A of Figure 15, which results in a significant 
increase in fluorescence at that point.26 Therefore, the protein-dye complex fluoresces at the 
temperature at which the protein denatures and the fluorescence can be plotted versus the 
increasing temperature to produce a melt curve analysis such as that shown in Figure 15B. 
The melt curve analysis can then be used to determine the shift in the melting temperature of 
the native, unbound protein compared to the ligand-bound protein. A significant increase in 
the melt temperature of the ligand-bound protein indicates that the stability of the protein is 
increased by its binding to the ligand. The ligand-protein interaction is therefore considered 
favorable. Within the context of this study, the oxidative metabolites of DEHP (1) would be 
predicted to bind to PPARγ and increase its melting temperature relative to the unbound 
PPARγ, indicating that the ligands are likely to bind to PPARγ and affect its transcription 
activity.  
 
Thermal Shift Assay using PPARγ and Rosiglitazone 
 The thermal shift assay was expected to provide information regarding the binding of 
DEHP (1), MEHP (2), and the secondary-oxidized metabolites 2cx-MMHP (9), 5oxo-MEHP 
(7), and 5cx-MEPP (8) to PPARγ LBD. In order to optimize the conditions required for 
PPARγ binding, the assay was first performed with known PPARγ ligand rosiglitazone. 
Rosiglitazone is used as an antidiabetic drug, and functions by stimulating PPARγ to activate 
the transcriptional cascade involved in adipogenesis.32 Since binding of a ligand to a protein 
typically stabilizes the structure of the protein and increases its melting temperature, this was 
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expected to be seen in the melt curve of PPARγ and rosiglitazone. Previous research 
suggested that PPARγ binding to rosiglitazone was optimal with rosiglitazone at a 
concentration of 200 µM; therefore, trials were performed with rosiglitazone at that 
concentration and above.33 Initially, given that PPARγ LBD was received in a buffer 
containing 50 mM Tris HCl, 100 mM NaCl, 1 mM TCEP, and 20% glycerol at pH 8.0, the 
entire assay was conducted using this buffer. Each well in use contained 5 µL of this buffer, 
along with 2.5 µL of dye, which was a proprietary mixture by ThermoFisher that 
emits/excites at ROX optical filter parameters, while experimental wells contained 3 µL, or 2 
µM of PPARγ LBD and varying concentrations of rosiglitazone between 100 µM and 200 
µM. The wells were then filled to 20 µL total with DI H2O. The melt curve of the assay 
conducted using the 50 mM Tris HCl, 100 mM NaCl, 1 mM TCEP, and 20% glycerol buffer 
at pH 8.0 is shown in Figure 16.  
 
 































As can be seen in Figure 16, the fluorescence emission was at too high an initial level and the 
emission expected from the denaturation of the protein was not able to be measured both 
without ligand and in the presence of ligand. There was no melt curve, which means the dye 
did not bind to the protein. This was potentially due to the fact that the proprietary dye 
mixture provided by ThermoFisher in the thermal shift assay kit was not designed to bind 
with membrane proteins or proteins in buffer containing hydrophobic elements.34  
Since the buffer used in the assay contained 20% glycerol, which is a hydrophobic 
molecule that may have interacted with the dye, it was determined that a 0.1 M phosphate 
buffer at pH 7.0 would be used in future assays. Additionally, given that that the dye mixture 
did not appear to bind sufficiently with the hydrophobic core of the PPARγ LBD when 
denaturation occurred, a new dye, SYPRO Orange, was selected, given that SYPRO Orange 
is a standard dye used in thermal shift assays.31 A second thermal shift assay was performed 
using PPARγ and rosiglitazone, but with the newly selected buffer and dye. The melt curve 






Figure 17. Melt curve of PPARγ with rosiglitazone in phosphate buffer and SYPRO Orange. 
 
 The melt curve shown in Figure 17 demonstrates the expected increase in 
fluorescence emission when the PPARγ LBD was denatured. Although the melt curve of the 
wells containing only PPARγ was out of proportion initially with the rest of the fluorescence, 
the obvious peaks in the wells containing rosiglitazone indicate that the protocol designed 
was effective. It is possible that the PPARγ began denaturing at a temperature below 25℃, 
which would explain the high fluorescence prior to reaching its expected TM, or the PPARγ 
LBD may have native fluorescence, so in the future it may be valuable to perform a TSA 
with the PPARγ unbound to SYPRO orange dye. The lack of a melt curve in the NPC and 
LOC wells indicates a lack of contamination as well as that there were no other fluorescence 
emitting substances besides the protein that would have skewed the results in the 
experimental wells. Using the first derivative of the fluorescence with respect to the 





























could be determined. Where the graph shows peaks and the slope is equal to zero is 
considered to be the TM. The first derivative graph is shown in Figure 18.  
 
 
Figure 18. Graph of the first derivative of the fluorescence with respect to the temperature. 
 
 The graph of the first derivative indicates the melting temperature of the protein. It 
can be seen that the PPARγ only well showed two melting points, the first of which had a 
greater fluorescence intensity. The first TM of the PPARγ not in the presence of rosiglitazone 
was 30.20℃, while the second TM was found to be 49.52℃. These temperatures were then 
used for comparison with the melting temperature of the protein in the presence of ligand. 
The first temperature determined from the assay is lower than that found in the literature, 
48.75 ± 0.08°C; however, the literature values were obtained using a TSA in a different 
buffer.35 The second TM of 49.52℃ is very similar to the literature. The first TM obtained is 
more similar to that determined by David Nunez and Dr. Kelli Slunt in their research on 






































experiment using the buffer cited in the literature in order to obtain temperatures that may be 
better analyzed.  
 In the experimental wells containing rosiglitazone, an increase in the TM can be seen. 
Based on the first derivative graph, it was determined that the TM of PPARγ in the presence 
of rosiglitazone increased to 52.87℃ for 200 µM and 51.94℃ for 400 µM added 
rosiglitazone. This indicated that the assay designed was successful in demonstrating the 
effect of ligand binding on the stability of PPARγ, which would allow further testing of 
ligands, such as DEHP (1), MEHP (2), and the secondary-oxidized metabolites (7-9) using 

















III. Conclusion and Future Work 
 All three secondary-oxidized metabolites were synthesized; however, analysis of the 
binding of the secondary oxidized metabolites (7-9) and MEHP (2) to PPARγ remains to be 
performed. Synthesis of the metabolites on a larger scale should be completed. Therefore, the 
synthetic scheme used to synthesize 5cx-MEPP (8) using the  enolate alkylation, is more 
efficient than using the malonic ester alkylation combined with the Krapcho decarboxylation. 
The length of time involved in the Krapcho decarboxylation is extensive, and often resulted 
in a product with significant impurities that were difficult to fully remove as shown in the 1H 
NMRs taken of 2-allylhexanoate (12) and 2-ethyl-5-hexenoate (17). While the Krapcho was 
an improvement on the KOH hydrolysis and subsequent decarboxylation with heat in terms 
of generating the desired product, the yield was usually low following purification, which 
would prove a hindrance in scaling up the reactions. Therefore, proposed synthetic 
mechanisms for 2cx-MMHP (9) and 5oxo-MEHP (7) using the enolate alkylation are shown 
in Scheme 12 and 13, respectively.  
 
 




Scheme 13. Synthesis of 5oxo-MEHP (7) using the enolate alkylation 
 
Once the metabolites have been synthesized in greater quantity, their binding with PPARγ 
can be tested using the TSA protocol developed. The dose response of PPARγ binding to the 
metabolites would be interesting to examine by performing the TSA with a variety of 
concentrations of the secondary-oxidized metabolites. 
 Additionally, since DEHP (1) is a chiral molecule, in the future it would be important 
to consider the effect of chirality on the binding of PPARγ and the secondary-oxidized 
metabolites. Enzymes, including PPARγ, are chiral molecules, and often show preference for 
one enantiomer of a chiral ligand over the other. The synthesis used to form 2cx-MMHP (9), 
5oxo-MEHP (7), and 5cx-MEPP (8) is racemic, meaning there is a mixture of the two 
possible enantiomers of the metabolites. In order to synthesize enantiomerically pure 
secondary-oxidized metabolites, an enzymatic resolution could be performed on the alcohol 
intermediates, 2-allylhexanol (13), 2-ethyl-5-hexen-1-ol (18), and 2-ethyl-6-hepten-1-ol (22). 
This could be done using Candida antarctica lipase to enantioselectively acylate the alcohol 
intermediates.36 The (S) enantiomer of the alcohol would be acylated with vinyl acetate, 
38 
 
yielding the (R) alcohol and (S) acetate. These would be separated using column 
chromatography and the (S) acetate would be reduced using LiAlH4 to produce the (S) 
alcohol. A proposed enzymatic resolution using 2-allylhexanol (13) is shown in Scheme 14.36  
 
 
Scheme 14. Enzymatic resolution of 2-allylhexanol (13) 
 
The enantiomerically pure resolved alcohol intermediates would then be used to synthesize 
enantiomerically pure secondary-oxidized metabolites that could be used to determine the 












The suppliers of all reagents and their purities are listed in the Materials subsection. 
Anhydrous tetrahydrofuran was dispensed from an MBraun Solvent Purification System. All 
chemicals were used as supplied unless otherwise specified. Purification of products was 
performed using column chromatography in a Biotage Isolera One flash chromatography 
system with Biotage silica gel columns. Gas Chromatography Mass Spectrometry (GC-MS) 
was performed on a Shimadzu GCMS-QP5050A. Nuclear Magnetic Resonance (NMR) of 
the oxidative metabolites was performed on a 400 MHz aOne NMR in CDCl3.  
Materials 
Reagent Supplier Purity 
Ethyl Ether Fisher Chemical Laboratory Grade 
Hexanes Fisher Chemical 99.9% 
Ethyl Acetate Honeywell >99.5% 
Methylene Chloride Fisher Chemical 99.9% 
Pyridine Fisher Chemical 99.9% 
Acetone Fisher Chemical 99.5% 
Methyl Sulfoxide ACROS Organics 99.9% 
Carbon Tetrachloride ACROS Organics 99.5% 
N,N-Dimethylformamide ACROS Organics 99.5% 
Iodoethane ACROS Organics 98% 
1-Iodobutane ACROS Organics 98% 
Diethyl allylmalonate Alfa Aesar 97% 
Ruthenium (III) Chloride Aldrich 99.98% 
Ethyl Butyrate ACROS Organics 99% 
Diethyl ethylmalonate ACROS Organics 99% 
Sodium Iodide ACROS Organics 98% 
Palladium (II) Chloride ACROS Organics 59% Pd 
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Lithium Chloride ACROS Organics 99+% 
p-Benzoquinone Alfa Aesar 98+% 
Phthalic Anhydride ACROS Organics 99% 
Sodium Meta Periodate Fisher Scientific Company 98% 
4-Bromo-1-butene ACROS Organics 98+% 
Lithium Aluminum Hydride 
Solution 
Aldrich 1.0 M in THF 
Sodium 
bis(trimethylsilyl)amide 
Aldrich 1.0 M in THF 




Fisher Chemical  
SYPRO Orange Protein Gel 
Stain 
SIGMA-ALDRICH 5000X concentration in 
DMSO 




Diethyl allylbutylmalonate (11). A round bottom flask and stir bar were dried in the oven 
and cooled under nitrogen. NaH (60% dispersion in mineral oil, 1.15 g, 28.8 mmol) was 
added and the flask was fitted with a septum before placing under nitrogen. THF (92 mL) 
was added and the flask was placed on an ice bath. The flask was cooled for 15 minutes 
before adding diethyl allylmalonate (4.81 g, 4.77 mL, 24 mmol). Bromobutane (4.93 g, 3.8 
mL, 36 mmol) was added after stirring the flask for 30 minutes at 0℃. The flask was then 
removed from the ice bath and nitrogen. NaI (1.8 g, 12 mmol) was added. The round-bottom 
flask was then placed under a condenser with a drying tube filled with glass wool and 
anhydrous calcium sulfate placed on top. The reaction was then refluxed at 65℃ overnight. 
The reaction was then quenched with DI H2O (100mL) and extracted with diethyl ether (3x 
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with 40 mL). The organic layers were combined and dried with MgSO4 and concentrated 
under vacuum. The resulting liquid was purified using flash column chromatography in 
hexanes/ethyl acetate with 5% ethyl acetate for 1 column volume (CV) followed by a 
gradient of 5-40% ethyl acetate for 10 CV and a final 40% ethyl acetate for 2 CV. Diethyl 
allylbutylmalonate (11) (5.75 g, 22.4 mmol, 78%) was obtained as a pale-yellow liquid. 1H 
NMR (400 MHz, CDCl3) δ 5.65 (dt, J = 16.9, 8.7 Hz, 1H), 5.07 (p, J = 8.6, 7.3 Hz, 2H), 4.17 
(p, J = 8.7, 7.9 Hz, 4H), 2.65 (t, J = 7.8 Hz, 2H), 1.87 (dq, J = 10.6, 6.9, 6.3 Hz, 2H), 1.66 – 
1.47 (m, 10H), 1.05 – 0.70 (m, 3H). 
2-Allylhexanoate (12). Diethyl allylbutylmalonate (11) (4.31 g, 16.8 mmol) was added to a 
250 mL round-bottom flask with a stir bar. DMSO (43 mL), LiCl (2.14 g, 50.4 mmol), and 
H2O (0.70 mL) were combined with diethyl allylbutylmalonate (11) and the flask was heated 
to 180℃ with stirring. The flask was heated for 10 hours and allowed to stir overnight. The 
reaction was quenched with H2O (150 mL) before extracting with ethyl acetate (3x with 100 
mL). The organic layers were combined and washed with brine (150 mL) and dried over 
MgSO4. The organic layers were then concentrated under vacuum. The resulting liquid was 
purified using flash column chromatography in hexanes/ethyl acetate with 5% ethyl acetate 
for 1 column volume (CV) followed by a gradient of 5-40% ethyl acetate for 10 CV and a 
final 40% ethyl acetate for 2 CV. 2-Allyl-hexanoate (2.91 g, 15.7 mmol, 50%) was obtained 
as a dark brown liquid. 1H NMR (400 MHz, CDCl3) δ 5.74 (ddt, J = 16.8, 10.2, 6.8 Hz, 1H), 
5.09 – 4.96 (m, 2H), 4.30 – 3.93 (m, 1H), 2.46 – 2.29 (m, 2H), 2.27 – 2.14 (m, 1H), 1.60 (qd, 




2-Allyl-1-hexanol (13). An oven-dried round-bottom flask with a two necked adapter and 
condenser was placed under nitrogen and on an ice bath. LiAlH4 (1M in THF, 0.80 g, 21.0 
mmol, 21.0 mL) was added to the oven-dried flask. In a separate flask a mixture of 2-Allyl-
hexanoate (12) (1.3 g, 7.04 mmol) in THF (50 mL) was made under nitrogen. The 2-Allyl-
hexanoate (12) in THF solution was added to the flask containing LiAlH4 dropwise. The 
reaction flask was heated to reflux at 40℃ for two hours. The reaction was then quenched by 
creating a slurry of 6M HCl (35 mL) in ice (70 g) and the reaction mixture was slowly 
poured over the slurry. The resulting mixture was extracted with diethyl ether (3x with 35 
mL). The organic layers were then combined and washed with brine (35 mL) before being 
dried over MgSO4 concentrated under vacuum. 2-Allyl-1-hexanol (4) (0.88 g, 6.19 mmol, 
89% crude) was obtained as a colorless liquid. 1H NMR (400 MHz, CDCl3) δ 5.82 (ddt, J = 
17.2, 10.1, 7.2 Hz, 1H), 5.22 – 4.83 (m, 2H), 3.80 – 3.70 (m, 1H), 3.56 (dd, J = 5.6, 4.1 Hz, 
2H), 2.03 (s, 3H), 1.68 – 1.46 (m, 2H), 1.45 – 1.09 (m, 4H), 0.97 (d, J = 6.6 Hz, 3H). 
Mono(2-allylhexyl) phthalate (14). A mixture containing 2-allyl-1-hexanol (13) (0.29 g, 2 
mmol), phthalic anhydride (0.30 g, 2 mmol), and pyridine (0.2 mL) was made in a round-
bottom flask and heated to reflux at 120℃ for three hours. The reaction was then allowed to 
stir overnight. The reaction mixture was diluted with H2O (15 mL) and extracted with diethyl 
ether (3x with 15 mL). The organic layers were combined and washed twice with 3M HCl 
(15 mL) before being dried over MgSO4 and concentrated under vacuum. The resulting 
mixture of crystals and liquid was dry loaded into a column and purified using flash column 
chromatography in hexanes/ethyl acetate with a gradient of 12% ethyl acetate for 1 CV, 12-
100% for 10 CV, and 100% for 2 CV. Mono(2-allylhexyl) phthalate (0.33 g, 1.14 mmol, 
58%) was obtained as a white crystalline solid. 1H NMR (400 MHz, CDCl3) δ 8.04 (dd, J = 
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5.8, 2.9 Hz, 1H), 7.96 (dd, J = 5.8, 3.0 Hz, 4H), 5.78 (dd, J = 17.1, 8.9 Hz, 1H), 5.12 – 4.88 
(m, 2H), 4.25 (t, J = 5.0 Hz, 2H), 2.15 (d, J = 7.6 Hz, 3H), 1.92 – 1.79 (m, 2H), 1.27 (q, J = 
10.1, 6.7 Hz, 4H), 1.00 (t, J = 7.6 Hz, 3H). 
2cx-MMHP (9). Mono(2-allylhexyl) phthalate (14) (0.22 g, 0.76 mmol), NaIO4 (0.67 g, 3.10 
mmol) and RuCl3 hydrate (3.46 mg, 0.017 mmol) were combined in a round-bottom flask. 
CCl4 (1.5 mL), CH3CN (1.5 mL), and H2O (2.3 mL) were added and the reaction flask was 
fitted to a septum and allowed to stir overnight. The reaction mixture was diluted with 
dichloromethane (10 mL) and H2O (23 mL) and extracted with dichloromethane (3x with 10 
mL). The organic layers were combined, dried over MgSO4, and concentrated under vacuum. 
The product was then purified with flash column chromatography dichloromethane/methanol 
plus 0.5% acetic acid with 2% methanol for 1 CV, followed by a gradient of 2-20% methanol 
for 10 CV, followed by 20% methanol for 2 CV. 2cx-MMHP (0.14 g, 0.45 mmol, 54%) was 
obtained as a viscous, rose-colored liquid. 1H NMR (400 MHz, CDCl3) δ 8.38 (s, 2H), 7.89 
(d, J = 7.6 Hz, 1H), 7.68 (d, J = 7.5 Hz, 1H), 7.64 – 7.51 (m, 2H), 4.43 (dd, J = 10.9, 4.2 Hz, 
2H), 2.55 (dd, J = 15.8, 6.9 Hz, 2H), 2.31 (tt, J = 12.6, 6.7 Hz, 3H), 1.62 – 1.14 (m, 4H), 0.89 
(t, J = 7.1 Hz, 3H). 
Diethyl (3-butenyl)ethyl malonate (16). A round-bottom flask and stir bar were dried in the 
oven and cooled under nitrogen. NaH (60% dispersion in mineral oil, 0.58 g, 14.4 mmol) was 
added and the flask was fitted with a septum before placing under nitrogen. THF (45 mL) 
was added and the flask was placed on an ice bath. The flask was cooled for 15 minutes 
before adding diethyl ethylmalonate (2.26 g, 2.25 mL, 12 mmol). After stirring 30 minutes 
on ice, 4-bromo-1-butene (2.43 g, 1.83 mL, 18 mmol) was added and the reaction flask was 
removed from the ice bath and the nitrogen was turned off. NaI (0.90 g, 6 mmol) was added 
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and the reaction was placed under a condenser with a drying tube containing glass wool and 
anhydrous calcium sulfate placed on top. The reaction was refluxed at 65℃ overnight. The 
reaction was quenched with H2O (50 mL) and extracted with diethyl ether (3x with 20 mL). 
The organic layers were combined, dried over MgSO4, and concentrated under vacuum. The 
resulting liquid was then purified with flash column chromatography in hexanes/ethyl acetate 
using a gradient of 5% ethyl acetate for 1 CV, 5-40% ethyl acetate for 10 CV, and 40% ethyl 
acetate for 2 CV. Diethyl (3-butenyl)ethyl malonate (8) (2.82 g, 11.6 mmol, 79%) was 
obtained. 1H NMR (400 MHz, CDCl3) δ 5.78 (ddt, J = 16.0, 11.1, 5.6 Hz, 1H), 4.99 (dd, J = 
29.6, 13.7 Hz, 2H), 4.18 (q, J = 7.1 Hz, 4H), 2.62 (d, J = 7.1 Hz, 7H), 1.95 (d, J = 7.6 Hz, 
2H), 1.44 – 1.19 (m, 6H). 
2-Ethyl-5-hexenoate (17). Diethyl (3-butenyl)ethyl malonate (16) (2.00 g, 8.25 mmol) was 
added to a round-bottom flask with a stir bar. DMSO (21 mL), LiCl (1.05 g, 24.8 mmol), and 
H2O (0.35 mL) were combined with diethyl (3-butenyl)ethyl malonate (16) and the flask was 
heated to 180℃ with stirring. The flask was heated for 16 hours and allowed to stir 
overnight. The reaction was quenched with H2O (75 mL) before extracting with hexanes (3x 
with 50 mL). The organic layers were combined and washed with brine (75 mL) and dried 
over MgSO4. The organic layers were then concentrated under vacuum. The resulting liquid 
was purified using flash column chromatography in hexanes/ethyl acetate with 5% ethyl 
acetate for 1 column volume (CV) followed by a gradient of 5-40% ethyl acetate for 10 CV 
and a final 40% ethyl acetate for 2 CV. 2-Ethyl-5-hexenoate (0.20 g, 1.17 mmol, 14%) was 
obtained as a dark brown liquid. 1H NMR (400 MHz, CDCl3) δ 5.93 – 5.59 (m, 1H), 5.24 – 
4.77 (m, 2H), 2.40 (t, J = 7.2 Hz, 2H), 2.15 – 1.86 (m, 2H), 1.74 – 1.66 (m, 7H), 1.27 (d, J = 
3.3 Hz, 3H). 
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2-Ethyl-5-hexen-1-ol (18). An oven-dried three-necked round-bottom flask with a condenser 
and stir bar placed under nitrogen and in an ice bath. LiAlH4 (1M in THF, 0.13 g, 3.52 mmol, 
3.50 mL) was added to the three-necked round-bottom flask. A mixture of 2-Ethyl-5-
hexenoate (17) (0.20 g, 1.17 mmol) in THF (8.80 mL) was created in a separate round-
bottom flask before being added to the three-necked flask dropwise. The three-necked 
reaction flask was then removed from the ice bath and heated to 40℃ for two hours with 
stirring. The reaction was allowed to stir overnight. The reaction was quenched by creating a 
slurry of 6M HCl (6 mL) in ice (12 g) and the reaction mixture was slowly poured over the 
slurry. The resulting mixture was extracted with diethyl ether (3x with 6 mL). The organic 
layers were then combined and washed with brine (6 mL) before being dried over MgSO4 
concentrated under vacuum. 2-Ethyl-5-hexenol (0.18 g, 1.40 mmol, 79% crude) was 
obtained. 1H NMR (400 MHz, CDCl3) δ 6.19 – 5.71 (m, 1H), 5.24 – 4.91 (m, 2H), 3.81 – 
3.66 (m, 1H), 3.60 – 3.50 (m, 2H), 2.35 – 1.99 (m, 3H), 1.51 – 1.34 (m, 4H), 1.03 – 0.77 (m, 
2H). 
Mono(2-ethyl-5-hexenyl) phthalate (19). A mixture containing 2-ethyl-5-hexenol (18) (0.18 
g, 1.4 mmol), phthalic anhydride (0.21 g, 1.4 mmol), and pyridine (0.15 mL) was made in a 
round-bottom flask and heated to reflux at 120℃ for two hours. The reaction was then 
allowed to stir overnight. The reaction mixture was diluted with H2O (10 mL) and extracted 
with diethyl ether (3x with 10 mL). The organic layers were combined and washed twice 
with 3M HCl (10 mL) before being dried over MgSO4 and concentrated under vacuum. The 
resulting crystalline solid was dry loaded into a column and purified using flash column 
chromatography in hexanes/ethyl acetate using a gradient of 12% ethyl acetate for 1 CV, 12-
100% ethyl acetate for 10 CV, and 100% ethyl acetate for 2 CV. Mono(2-ethyl-5-hexenyl) 
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phthalate (0.24 g, 0.87 mmol, 81%) was obtained as a white crystalline solid. 1H NMR (400 
MHz, CDCl3) δ 8.07 (dd, J = 5.6, 3.1 Hz, 1H), 7.72 – 7.60 (m, 4H), 5.87 – 5.80 (m, 1H), 
5.02 (dd, J = 28.8, 13.8 Hz, 2H), 4.31 (d, J = 5.6 Hz, 2H), 2.14 (q, J = 7.4 Hz, 3H), 1.60 – 
1.38 (m, 4H), 0.96 (t, J = 7.5 Hz, 3H). 
5oxo-MEHP (7). A mixture of DMF (2.10 mL) and H2O (0.30 mL) was made and half of the 
solution was added to a round-bottom flask containing mono(2-ethyl-5-hexenyl) phthalate 
(19) (0.24 g, 0.87 mmol) and a stir bar. PdCl2 (1.70 mg, 0.0087 mmol) and p-benzoquinone 
(0.10 g, 0.96 mmol) were dissolved in the remaining DMF/H2O. The PdCl2 and p-
benzoquinone mixture in DMF/H2O was added to the flask containing mono(2-ethyl-5-
hexenyl) phthalate (19). The reaction was stirred at room temperature overnight. The reaction 
was quenched with 3M HCl (6 ml) and extracted with diethyl ether (3x with 10 mL). The 
organic layers were combined, washed with brine (6 mL), dried over MgSO4, and 
concentrated under vacuum. 5oxo-MEHP (0.22 g, 0.75 mmol, 86% crude) was obtained as a 
mixture of orange-colored crystals and liquid. 1H NMR (400 MHz, CDCl3) δ 8.01 (s, 1H), 
7.55 – 7.52 (m, 4H), 4.11 (d, J = 7.1 Hz, 2H), 2.99 (d, J = 1.3 Hz, 3H), 2.88 (s, 2H), 2.04 (s, 
2H), 1.19 (t, J = 7.0 Hz, 6H). 
5-Iodo-1-pentene (24). Sodium iodide (10.0 g, 66.8 mmol) was dissolved in acetone (36 
mL) in a round-bottom flask. 5-Bromo-1-pentene (5.96 g, 40 mmol, 4.73 mL) was added to 
the flask. The mixture was heated to 50℃ with stirring for one hour. Fractional distillation 
was used to distill off the acetone, leaving the product behind. Once only the product 
remained in the flask, DI H2O (20 mL) was added to the flask. The product was then 
extracted with ethyl ether (3x with 20 mL). The organic layers were combined and washed 
sequentially with H2O (20 mL), saturated sodium sulfite (20 mL), and brine (20 mL). The 
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organic layers were then dried with MgSO4 and concentrated under vacuum. 5-Iodo-1-
pentene (7.47 g, 38.1 mmol, 95% crude) was obtained as a light-yellow liquid. Stored in a 
refrigerator at 8 ℃. 
Diethyl (3-pentenyl)ethyl malonate (20). A round-bottom flask and stir bar were dried in 
the oven and cooled under nitrogen. NaH (60% dispersion in mineral oil, 0.29 g, 7.2 mmol) 
was added and the flask was fitted with a septum before placing under nitrogen. THF (23 
mL) was added and the flask was placed on an ice bath. The flask was cooled for 15 minutes 
before adding diethyl ethylmalonate (1.13 g, 1.12 mL, 6 mmol). After stirring 30 minutes on 
ice, 5-bromo-1-pentene (1.34 g, 1.07 mL, 9 mmol) was added and the reaction flask was 
removed from the ice bath and the nitrogen was turned off. NaI (0.45 g, 3 mmol) was added 
and the reaction was placed under a condenser with a drying tube containing glass wool and 
anhydrous calcium sulfate placed on top. The reaction was refluxed at 65℃ overnight. The 
reaction was quenched with H2O (25 mL) and extracted with diethyl ether (3x with 10 mL). 
The organic layers were combined, dried over MgSO4, and concentrated under vacuum. 
Diethyl (3-pentenyl)ethyl malonate (20) (1.46 g, 5.70 mmol, 94% crude) was obtained as a 
yellow-orange liquid.  
ethyl 2-ethyl-6-heptenoate (21a). Diethyl (3-pentenyl)ethyl malonate (20) (1.35 g, 5.27 
mmol) was added to a round-bottom flask with a stir bar. DMSO (13.4 mL), LiCl (0.67 g, 
15.8 mmol), and H2O (0.23 mL) were combined with diethyl (3-pentenyl)ethyl malonate and 
the flask was heated to 180℃ with stirring. The flask was heated for 15 hours and allowed to 
stir overnight. The reaction was quenched with H2O (47 mL) before extracting with hexanes 
(3x with 30 mL). The organic layers were combined and washed with brine (47 mL) and 
dried over MgSO4. The organic layers were then concentrated under vacuum. The resulting 
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liquid was purified using flash column chromatography in hexanes/ethyl acetate with 5% 
ethyl acetate for 1 column volume (CV) followed by a gradient of 5-40% ethyl acetate for 10 
CV and a final 40% ethyl acetate for 2 CV. Ethyl 2-ethyl-6-heptenoate (0.22 g, 1.19 mmol, 
10%) was obtained as a viscous dark brown liquid. 
ethyl 2-ethyl-6-heptenoate (21b). Ethyl butyrate (1.17g, 10.0 mmol) was mixed with THF 
(20 mL) under nitrogen in a round-bottom flask containing a stir bar and fitted with a septum. 
The reaction flask was placed in an acetone bath and cooled to -78℃ for 15 minutes. 
NaHMDS (12 mL) was added and allowed to react for 30 minutes while in the acetone bath. 
5-Iodo-1-pentene (24) (3.92 g, 20 mmol, 2.45 mL) was added to the reaction flask and the 
flask was removed from the acetone bath. The reaction was allowed to stir overnight. The 
reaction mixture was quenched with 1M HCl (50 mL) and extracted  with ethyl ether (3x 
with 50 mL). The organic layers were combined and dried over MgSO4 before being 
concentrated under vacuum. The resulting liquid was purified using flash column 
chromatography in hexanes ethyl acetate with 5% ethyl acetate for 1 CV followed by a 
gradient of 5-40% ethyl acetate for 10 CV and a final 40% ethyl acetate for 2 CV. Ethyl 2-
ethyl-6-heptenoate (1.17 g, 6.34 mmol, 63%) was obtained as a transparent liquid. 1H NMR 
(400 MHz, CDCl3) δ 5.77 (ddd, J = 17.0, 10.2, 6.6 Hz, 1H), 5.05 – 4.90 (m, 2H), 4.16 (dq, J 
= 14.0, 7.0 Hz, 2H), 2.36 (t, J = 7.2 Hz, 1H), 2.06 (q, J = 6.8 Hz, 2H), 1.44 – 1.17 (m, 9H), 
0.97 (d, J = 6.6 Hz, 3H). 
2-ethyl-6-hepten-1-ol (22). An oven-dried three-necked round-bottom flask with a 
condenser and stir bar placed under nitrogen and in an ice bath. LiAlH4 (1M in THF, 0.31 g, 
8.14 mmol, 8.14 mL) was added to the three-necked round-bottom flask. A mixture of ethyl 
2-ethyl-6-heptenoate (21b) (0.50 g, 2.71 mmol) in THF (20 mL) was created in a separate 
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round-bottom flask before being added to the three-necked flask dropwise. The three-necked 
reaction flask was then removed from the ice bath and heated to 40℃ for two hours with 
stirring. The reaction was allowed to stir overnight. The reaction was quenched by creating a 
slurry of 6M HCl (14 mL) in ice (25 g) and the reaction mixture was slowly poured over the 
slurry. The resulting mixture was extracted with diethyl ether (3x with 15 mL). The organic 
layers were then combined and washed with brine (15 mL) before being dried over MgSO4 
concentrated under vacuum. 2-ethyl-6-heptenol (0.35 g, 2.46 mmol, 86% crude) was 
obtained. 1H NMR (400 MHz, CDCl3) δ 5.40 (s, 1H), 5.09 – 4.86 (m, 2H), 3.81 (s, 1H), 3.25 
(d, J = 6.7 Hz, 2H), 2.04 (d, J = 50.9 Hz, 2H), 1.49 (d, J = 1.5 Hz, 1H), 1.20 (s, 6H), 0.90 (d, 
J = 6.7 Hz, 3H). 
Mono(2-ethyl-6-heptenyl) phthalate (23). A mixture containing 2-ethyl-6-heptenol (22) 
(0.32 g, 2.25 mmol), phthalic anhydride (0.36 g, 2.25 mmol), and pyridine (0.21 mL) was 
made in a round-bottom flask and heated to reflux at 120℃ for two hours. The reaction was 
then allowed to stir overnight. The reaction mixture was diluted with H2O (10 mL) and 
extracted with diethyl ether (3x with 10 mL). The organic layers were combined and washed 
twice with 3M HCl (10 mL) before being dried over MgSO4 and concentrated under vacuum. 
The resulting crystalline solid was dry loaded onto a column and purified using flash column 
chromatography using hexanes/ethyl acetate with a gradient of 12% ethyl acetate for 1 CV, 
12-100% ethyl acetate for 10 CV, and 100% ethyl acetate for 2 CV. Mono(2-ethyl-6-
heptenyl) phthalate (0.47 g, 1.62 mmol, 49%) was obtained as a white crystalline solid. 1H 
NMR (400 MHz, CDCl3) δ 7.88 – 7.74 (m, 1H), 7.54 – 7.39 (m, 4H), 5.70 (td, J = 10.2, 5.2 




5cx-MEPP (8). Mono(2-ethyl-6-heptenyl) phthalate (23) (0.30 g, 1.03 mmol), NaIO4 (0.90 g, 
4.22 mmol) and RuCl3 hydrate (4.71 mg, 0.023 mmol) were combined in a round-bottom 
flask. CCl4 (2.0 mL), CH3CN (2.0 mL), and H2O (3.1 mL) were added and the reaction flask 
was fitted to a septum and allowed to stir overnight. The reaction mixture was diluted with 
dichloromethane (11 mL) and H2O (24 mL) and extracted with dichloromethane (3x with 11 
mL). The organic layers were combined, dried over MgSO4, and concentrated under vacuum. 
The product was then purified with flash column chromatography dichloromethane/methanol 
plus 0.5% acetic acid with 2% methanol for 1 CV, followed by a gradient of 2-20% methanol 
for 10 CV, followed by 20% methanol for 2 CV. 5cx-MEPP (0.21 g, 0.54 mmol, 35%) was 
obtained as a viscous, purple-black liquid. 1H NMR (400 MHz, CDCl3) δ 7.85 – 7.75 (m, 
1H), 7.66 – 7.59 (m, 1H), 7.58 – 7.42 (m, 2H), 4.26 – 4.11 (m, 2H), 2.33 (t, J = 7.4 Hz, 2H), 
1.67 – 1.59 (m, 10H). 
 
Thermal Shift Assay Protocol 
The TSAs were carried out using the melt curve function of a QuantStudio 3 qRT-PCR. A 
stock solution of PPARγ LBD of 0.5 µg/µL in 50 mM Tris HCl, 100 mM NaCl, 1 mM 
TCEP, and 20% glycerol at pH 8.0 was made and stored at -80℃. A fresh solution of the 
PPARγ ligand rosiglitazone of 1 mM in DMSO was created each time the assay was 
performed. SYPRO Orange 5000X dye was diluted with DI H2O to 80X stock each time the 
assay was performed. A 96-well plate was used in the assays and wells were filled to 20 µL 
total solution containing 0.1 M phosphate buffer at pH 7.0, DI H2O, SYPRO Orange dye, 
PPARγ LBD, and the ligand of interest. A no protein control (NPC) and ligand only control 
(LOC) were used to ensure accuracy of the melt curve and to ensure that there were no 
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ligand-dye interactions or impurities in the buffer that would cause fluorescence in the 
control wells. In the NPC wells, 0.1 M phosphate buffer (5 µL), SYPRO Orange dye (2.5 µL, 
10X concentration), and DI H2O (12.5 µL) were mixed by pipetting up and down several 
times. In LOC wells, 0.1 M phosphate buffer (5.0 µL), SYPRO Orange dye (2.5 µL, 10X 
final concentration), DI H2O (10.5 µL), and the ligand of interest (2.0 µL, 0.2 mM final 
concentration) were added. In the reaction wells, PPARγ LBD (3.0 µL, 2.0 µM final 
concentration) was added along with the ligand of interest (varying concentrations), and 0.1 
M phosphate buffer (5.0 µL), SYPRO Orange dye (2.5 µL, 10X final concentration), were 
mixed and DI H2O was added until a total volume of 20 µL was reached. The 96-well plate 
was then sealed and centrifuged at 800 g for 1 minute. The QuantStudio 3 qRT-PCR was set 
using the following parameters:  
Experiment Type: Melt Curve  
Reagents: Other 
Ramp: Standard 
Reporter: SYPRO Orange 
Quencher: None 
Passive Reference: None 
Ramp Mode: Continuous 
Thermal Profile: Step 1 – 25℃, 2 minutes, 1.6℃/s 
      Step 2 – 99℃, 2 minutes, 0.05℃/s 
Optical Filters: Excitation – x4(580 ±10) 
    Emission – m4(623±14) 
 
Targets were set for all wells in use and the melt curve experiment was run. The melt curve 
results were analyzed using Excel, and the melt temperature for each well in which a melt 
curve was obtained was estimated by taking the first derivative of the fluorescence emission 
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Appendix A. NMR Spectra 
 

























































Appendix B. GC-MS Spectra 











































































































































Figure 41. GC-MS of crude 2-ethyl-6-hepten-1-ol (22) 
 
 
 
 
 
 
